Thyrocare Technologies Ltd (BOM:539871)
₹ 820.25 -11.25 (-1.35%) Market Cap: 43.52 Bil Enterprise Value: 42.48 Bil PE Ratio: 56.21 PB Ratio: 8.31 GF Score: 80/100

Q2 2021 Thyrocare Technologies Ltd Earnings Call Transcript

Nov 03, 2020 / 06:30AM GMT
Release Date Price: ₹1142.55 (-0.67%)
Operator

I'm sorry sir, you are not very clear. You are not audible.

Unidentified Company Representative

Am I now?

Operator

Yes, sir.

Unidentified Company Representative

So I'll run out through some key highlights of quarterly results as well as quarterly financial results, which we have filed on 28th of October. And a brief presentation, which we have filed on the same day. Our stand-alone revenue for the current quarter stands at INR 148.54 crore, which is roughly 38% higher as compared to Y-o-Y same quarter last financial year.

We have seen a good revision in the current quarter. Our non COVID revenue has revised to the extent of 94% in the current quarter. Our current quarter core revenue stands about INR 48 crore. We have done about INR 2.76 lakh COVID RT-PCR investigation in the current quarter. As far as Nueclear is concerned, that is radiology arm of Thyrocare Group. They have achieved a total turnover of INR 4.71 crore in the current quarter. There, we could not see a good revival, but

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot